Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL)

Sol-Gel Technologies (NASDAQ:SLGL) outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin cancers and other man

The company’s diluted loss per share came in at $3.2, exceeding an estimated loss of $1.2.

SLGL stock results show that Sol-Gel Technologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

SLGL stock results show that Sol-Gel Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones.

  On Thursday, 369 companies hit new 52-week lows.

  Friday's session saw 112 companies set new 52-week lows.

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

Although penny stocks represent extremely high risks, a select few ideas could make for enticing long-term propositions.

  On Tuesday, 386 stocks made new 52-week lows.

  Friday's session saw 169 companies set new 52-week lows.

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at $3.21 on Friday.

The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them.

Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday.

U.S. stocks traded mostly higher midway through trading, with the Dow Jones surging more than 300 points on Monday.

Upgrades